안과 의학 시장 분석 및 예측(-2035년) : 유형, 제품, 기술, 용도, 형태, 디바이스, 최종 사용자, 기능, 솔루션

The global ophthalmic medicine market is projected to grow from $39.6 billion in 2025 to $90.2 billion by 2035, at a compound annual growth rate (CAGR) of 8.6%. The global ophthalmic drugs market continues to expand as aging populations, diabetes-related eye complications, and increasing diagnosis of glaucoma, retinal diseases, and dry-eye conditions strengthen treatment demand. The U.S. Food and Drug Administration maintains extensive regulatory activity across ophthalmic drug products, while the National Eye Institute reports that millions of Americans are affected by major vision and eye conditions, supporting a substantial addressable patient base. Globally, demand is shifting toward biologics, biosimilars, sustained-release formulations, and specialized therapies for retinal disorders. Market growth is further supported by rising healthcare expenditure, improved ophthalmic screening, expanding clinical pipelines, and increasing access to advanced vision-care services.

The market is structured around prescription drugs, over-the-counter drugs, biologics, biosimilars, and other specialized ophthalmic medicines. Prescription drugs remain central to chronic disease management, particularly glaucoma, retinal disorders, and ocular inflammation, while over-the-counter products address high-volume conditions such as dry eye and minor irritation. Biologics are increasingly important for retinal vascular diseases and inflammatory disorders because of their targeted mechanisms and clinical efficacy. Biosimilars are expanding access to high-cost biologic treatments by supporting price competition and broader patient affordability. The segment outlook remains favorable, supported by aging populations, rising diabetes prevalence, increasing ophthalmic disease diagnosis, and continued development of innovative therapies.

Technology segmentation includes gene therapy, stem cell therapy, nanotechnology, drug delivery systems, and other emerging platforms. Gene therapy is gaining attention for inherited retinal disorders by targeting underlying genetic abnormalities, while stem cell approaches seek to restore or replace damaged ocular tissues. Nanotechnology supports improved drug stability, bioavailability, and targeted delivery, whereas advanced drug delivery systems, including sustained-release implants and ocular inserts, aim to reduce dosing frequency and improve treatment adherence. These technologies are transforming ophthalmic therapeutics by addressing limitations associated with conventional eye drops and injections. Growth prospects are supported by biotechnology investment, clinical research, precision medicine, and increasing demand for durable treatment solutions.

Geographical Overview

North America maintains a leading position in the ophthalmic medicine market, supported by advanced healthcare infrastructure, high diagnosis and treatment rates, and substantial pharmaceutical and biotechnology capabilities. The United States represents the region's primary demand base, with significant prevalence of age-related macular degeneration, diabetic retinopathy, glaucoma, and dry-eye disease. Strong specialist networks, advanced ophthalmic surgical centers, reimbursement mechanisms, and high healthcare expenditure reinforce market penetration. The region also benefits from extensive research and development activity, venture investment, and regulatory support for innovative therapies. Established clinical trial infrastructure and rapid adoption of biologics, biosimilars, gene therapies, and advanced drug delivery technologies are expected to sustain its commercial importance.

Asia-Pacific presents substantial expansion opportunities due to its large population base, increasing prevalence of diabetes and age-related eye disorders, improving healthcare access, and growing awareness of vision preservation. China, Japan, India, South Korea, and other emerging economies are strengthening pharmaceutical manufacturing and ophthalmic care infrastructure, while domestic and multinational companies continue expanding production, distribution, and research capabilities. Government healthcare initiatives, rising insurance coverage, urbanization, and investments in specialty hospitals are improving access to ophthalmic treatments. Increasing adoption of innovative biologics, affordable biosimilars, and advanced delivery systems is expected to broaden treatment availability, while expanding clinical research and local manufacturing capacity will support long-term regional market development.

Key Trends and Drivers

The Shift Toward Precision and Long-Acting Eye Therapies:

The ophthalmic medicine market is increasingly shifting toward long-acting, targeted, and precision-based therapies that improve clinical outcomes while reducing treatment frequency. Biologics and biosimilars are gaining importance in retinal disease management, while sustained-release implants, injectable formulations, nanotechnology, and novel ocular delivery platforms are being developed to overcome the limited absorption and short residence time associated with conventional eye drops. Gene therapies are also advancing the therapeutic landscape for selected inherited retinal disorders. This transition reflects growing demand for patient-centric treatment models, improved adherence, durable therapeutic effects, and solutions capable of addressing complex chronic and vision-threatening conditions.

Rising Global Burden of Vision-Threatening Eye Disorders:

The rising global burden of ophthalmic disorders is a primary market growth driver, reinforced by population aging, increasing diabetes prevalence, longer life expectancy, and improved disease detection. Age-related macular degeneration, diabetic retinopathy, glaucoma, and dry-eye disease are generating sustained demand for pharmacological intervention and long-term disease management. Greater awareness of eye health and expanded screening programs are increasing diagnosis rates, while healthcare infrastructure improvements are enabling more patients to access specialist treatment. In parallel, pharmaceutical innovation is broadening therapeutic options through biologics, biosimilars, gene-based treatments, and advanced drug delivery systems, creating additional opportunities for market expansion.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by Form
• 2.6 Key Market Highlights by Device
• 2.7 Key Market Highlights by End User
• 2.8 Key Market Highlights by Functionality
• 2.9 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Prescription Drugs
  • 4.1.2 Over-the-Counter Drugs
  • 4.1.3 Biologics
  • 4.1.4 Biosimilars
  • 4.1.5 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Eye Drops
  • 4.2.2 Ointments
  • 4.2.3 Capsules and Tablets
  • 4.2.4 Injectables
  • 4.2.5 Gels
  • 4.2.6 Implants
  • 4.2.7 Others
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Gene Therapy
  • 4.3.2 Stem Cell Therapy
  • 4.3.3 Nanotechnology
  • 4.3.4 Drug Delivery Systems
  • 4.3.5 Others
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Glaucoma
  • 4.4.2 Dry Eye Syndrome
  • 4.4.3 Retinal Disorders
  • 4.4.4 Allergic Conjunctivitis
  • 4.4.5 Uveitis
  • 4.4.6 Others
• 4.5 Market Size & Forecast by Form (2020-2035)
  • 4.5.1 Liquid
  • 4.5.2 Solid
  • 4.5.3 Semi-Solid
  • 4.5.4 Others
• 4.6 Market Size & Forecast by Device (2020-2035)
  • 4.6.1 Intraocular Lenses
  • 4.6.2 Contact Lenses
  • 4.6.3 Ophthalmic Lasers
  • 4.6.4 Diagnostic Devices
  • 4.6.5 Others
• 4.7 Market Size & Forecast by End User (2020-2035)
  • 4.7.1 Hospitals
  • 4.7.2 Ophthalmic Clinics
  • 4.7.3 Retail Pharmacies
  • 4.7.4 Online Pharmacies
  • 4.7.5 Others
• 4.8 Market Size & Forecast by Functionality (2020-2035)
  • 4.8.1 Anti-inflammatory
  • 4.8.2 Anti-infective
  • 4.8.3 Anti-glaucoma
  • 4.8.4 Anti-allergy
  • 4.8.5 Others
• 4.9 Market Size & Forecast by Solutions (2020-2035)
  • 4.9.1 Vision Care
  • 4.9.2 Surgical Solutions
  • 4.9.3 Diagnostic Solutions
  • 4.9.4 Therapeutic Solutions
  • 4.9.5 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 Form
    • 5.2.1.6 Device
    • 5.2.1.7 End User
    • 5.2.1.8 Functionality
    • 5.2.1.9 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 Form
    • 5.2.2.6 Device
    • 5.2.2.7 End User
    • 5.2.2.8 Functionality
    • 5.2.2.9 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 Form
    • 5.2.3.6 Device
    • 5.2.3.7 End User
    • 5.2.3.8 Functionality
    • 5.2.3.9 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 Form
    • 5.3.1.6 Device
    • 5.3.1.7 End User
    • 5.3.1.8 Functionality
    • 5.3.1.9 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 Form
    • 5.3.2.6 Device
    • 5.3.2.7 End User
    • 5.3.2.8 Functionality
    • 5.3.2.9 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 Form
    • 5.3.3.6 Device
    • 5.3.3.7 End User
    • 5.3.3.8 Functionality
    • 5.3.3.9 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 Form
    • 5.4.1.6 Device
    • 5.4.1.7 End User
    • 5.4.1.8 Functionality
    • 5.4.1.9 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 Form
    • 5.4.2.6 Device
    • 5.4.2.7 End User
    • 5.4.2.8 Functionality
    • 5.4.2.9 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 Form
    • 5.4.3.6 Device
    • 5.4.3.7 End User
    • 5.4.3.8 Functionality
    • 5.4.3.9 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 Form
    • 5.4.4.6 Device
    • 5.4.4.7 End User
    • 5.4.4.8 Functionality
    • 5.4.4.9 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 Form
    • 5.4.5.6 Device
    • 5.4.5.7 End User
    • 5.4.5.8 Functionality
    • 5.4.5.9 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 Form
    • 5.4.6.6 Device
    • 5.4.6.7 End User
    • 5.4.6.8 Functionality
    • 5.4.6.9 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 Form
    • 5.4.7.6 Device
    • 5.4.7.7 End User
    • 5.4.7.8 Functionality
    • 5.4.7.9 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 Form
    • 5.5.1.6 Device
    • 5.5.1.7 End User
    • 5.5.1.8 Functionality
    • 5.5.1.9 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 Form
    • 5.5.2.6 Device
    • 5.5.2.7 End User
    • 5.5.2.8 Functionality
    • 5.5.2.9 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 Form
    • 5.5.3.6 Device
    • 5.5.3.7 End User
    • 5.5.3.8 Functionality
    • 5.5.3.9 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 Form
    • 5.5.4.6 Device
    • 5.5.4.7 End User
    • 5.5.4.8 Functionality
    • 5.5.4.9 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 Form
    • 5.5.5.6 Device
    • 5.5.5.7 End User
    • 5.5.5.8 Functionality
    • 5.5.5.9 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 Form
    • 5.5.6.6 Device
    • 5.5.6.7 End User
    • 5.5.6.8 Functionality
    • 5.5.6.9 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 Form
    • 5.6.1.6 Device
    • 5.6.1.7 End User
    • 5.6.1.8 Functionality
    • 5.6.1.9 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 Form
    • 5.6.2.6 Device
    • 5.6.2.7 End User
    • 5.6.2.8 Functionality
    • 5.6.2.9 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 Form
    • 5.6.3.6 Device
    • 5.6.3.7 End User
    • 5.6.3.8 Functionality
    • 5.6.3.9 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 Form
    • 5.6.4.6 Device
    • 5.6.4.7 End User
    • 5.6.4.8 Functionality
    • 5.6.4.9 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 Form
    • 5.6.5.6 Device
    • 5.6.5.7 End User
    • 5.6.5.8 Functionality
    • 5.6.5.9 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Novartis
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Roche
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Allergan
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Bausch Health
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Alcon
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Johnson and Johnson
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Bayer
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Pfizer
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Santen Pharmaceutical
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Regeneron Pharmaceuticals
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Sun Pharmaceutical
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Aerie Pharmaceuticals
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Otsuka Pharmaceutical
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Teva Pharmaceutical
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 AbbVie
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Sanofi
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 GlaxoSmithKline
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 AstraZeneca
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Merck
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Eli Lilly
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us